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Abstract
Resistance to erythropoiesis stimulating agents (ESA) is common in patients undergoing chronic hemodialysis (HD)
treatment. ESA responsiveness might be improved by enhanced clearance of uremic toxins of middle molecular weight, as
can be obtained by hemodiafiltration (HDF). In this analysis of the randomized controlled CONvective TRAnsport STudy
(CONTRAST; NCT00205556), the effect of online HDF on ESA resistance and iron parameters was studied. This was a pre-
specified secondary endpoint of the main trial. A 12 months’ analysis of 714 patients randomized to either treatment with
online post-dilution HDF or continuation of low-flux HD was performed. Both groups were treated with ultrapure dialysis
fluids. ESA resistance, measured every three months, was expressed as the ESA index (weight adjusted weekly ESA dose in
daily defined doses [DDD]/hematocrit). The mean ESA index during 12 months was not different between patients treated
with HDF or HD (mean difference HDF versus HD over time 0.029 DDD/kg/Hct/week [20.024 to 0.081]; P = 0.29). Mean
transferrin saturation ratio and ferritin levels during the study tended to be lower in patients treated with HDF (22.52%
[24.72 to 20.31]; P = 0.02 and 249 ng/mL [2103 to 4]; P = 0.06 respectively), although there was a trend for those patients
to receive slightly more iron supplementation (7.1 mg/week [20.4 to 14.5]; P = 0.06). In conclusion, compared to low-flux
HD with ultrapure dialysis fluid, treatment with online HDF did not result in a decrease in ESA resistance.
Trial Registration: ClinicalTrials.gov NCT00205556
Citation: van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, et al. (2014) Resistance to Erythropoiesis Stimulating Agents in Patients
Treated with Online Hemodiafiltration and Ultrapure Low-Flux Hemodialysis: Results from a Randomized Controlled Trial (CONTRAST). PLoS ONE 9(4): e94434.
doi:10.1371/journal.pone.0094434
Editor: Robert K. Hills, Cardiff University, United Kingdom
Received November 8, 2013; Accepted March 14, 2014; Published April 17, 2014
Copyright:  2014 van der Weerd et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CONTRAST is financially supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland, grant C02.2019) and unrestricted grants
from Fresenius Medical Care (The Netherlands) and Gambro Lundia AB (Sweden). Additional support was received from the Dr. E.E. Twiss Fund, Roche
Netherlands, the International Society of Nephrology/Baxter Extramural Grant Program, and the Dutch Organization for Health Research and Development
(ZonMW, grant 17088.2802). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: As can be seen at the Financial Disclosure section, funding for the CONTRAST study was obtained from commercial sources (Fresenius
Medical Care, Gambro Lundia AB and Roche Netherlands). However, this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and
materials.
* E-mail: n.c.vanderweerd@amc.uva.nl
" Membership of the CONTRAST Investigators is provided in the Acknowledgments.
Introduction
In chronic hemodialysis (HD) patients, renal anemia is generally
treated with erythropoiesis stimulating agents (ESA) and iron
supplements. Although treatment with ESA has been shown to
improve left ventricular mass index [1] and quality of life [2], ESA
treatment has not been associated with a survival benefit, neither
in HD patients [3] nor in patients with chronic kidney disease not
yet on dialysis [4,5,6]. In many HD patients, target hemoglobin
levels are not reached due to a varying degree of ESA resistance. A
diminished response to ESA has been associated with various
factors, including (functional) iron deficiency, an impaired
nutritional state and the presence of (micro)inflammation [7,8].
Furthermore, the microbiological purity of the dialysis fluid [9],
the presence of hyperparathyroidism [10] and low dialysis
adequacy [11] have been associated with ESA resistance.
Hemodiafiltration (HDF) is an extracorporeal renal replace-
ment therapy that combines diffusive and convective solute
removal. In comparison with conventional HD, removal of
substances in the middle molecular weight (MMW) range (0.5–
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40 kilodalton) is enhanced. Several observational studies showed a
survival benefit in patients treated with HDF [12,13,14,15],
whereas in the randomized controlled CONvective TRAnsport
STudy (CONTRAST) study and the Turkish Online Hemodiafil-
tration Study, survival was similar in patients treated with online
HDF and conventional HD [16,17]. The recently published
randomized On-Line Hemodiafiltration Survival Study (ESHOL)
did show a survival advantage for patients treated with HDF,
however [18].
It has been suggested that adding convective solute removal
improves ESA resistance, and hence the degree of anemia,
possibly by removing MMW toxins with erythropoiesis inhibiting
properties [19,20], increasing red blood cell life span [21,22] and/
or improving iron utilization [23]. Clinical data on the effect of
HDF on ESA resistance, however, are conflicting (table 1).
Anemia management and ESA resistance were predefined
secondary endpoints of the CONTRAST study [16,24]. In the
present analysis of this randomized controlled trial (RCT), the
effect of online post-dilution HDF and ultrapure low-flux HD on
hemoglobin levels, ESA resistance and iron parameters was
evaluated over a 12 month period.
Materials and Methods
Patients and study design
In the CONTRAST study (clinicaltrials.gov identifier
NCT00205556; first registration on September 2005), 714 chronic
HD patients were randomized either to switch to online HDF or to
continue low-flux HD. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1. The study was conducted in
accordance with the Declaration of Helsinki and was approved by
a central medical ethics committee and by all local medical ethics
review boards. Written informed consent was obtained from all
patients prior to enrolment. Central approval was obtained by the
Medical Ethical Committee of the VU University Medical Center.
Local approval was obtained from the Medical Ethical Commit-
tees of all participating centers, which are listed in the
acknowledgements. The enrolment period started in June 2004
and ended on January 1st 2010. The study stopped on January 1st
2011. For the present analysis, all available data on anemia
management and ESA resistance until 12 months of follow-up
were evaluated. Anemia management and ESA resistance was a
pre-specified secondary endpoint of the study and as such
registered on clinicaltrials.gov. The trial registration date of the
study was slightly after enrolment started due to logistic reasons.
The authors confirm that all related trials for this treatment
intervention are registered.
The rationale and the design of the CONTRAST study have
been described before [24]. Primary endpoint of the study is all
cause mortality [16]. Patients were recruited from 26 dialysis
centers in The Netherlands, 2 centers in Canada and 1 center in
Norway and randomized centrally into a 1:1 ratio for treatment
with online HDF or continuation of low-flux HD, stratified per
participating center. Patients were eligible for inclusion if they
were treated two or three times per week with HD for at least two
months. Exclusion criteria were age below 18 years, treatment
with hemo(dia)filtration or high-flux HD in six months prior to
randomization, a life expectancy less than three months due to
non-renal disease, participation in another clinical intervention
trial evaluating cardiovascular outcomes and severe incompliance
regarding frequency and/or duration of dialysis treatment.
Treatment protocol
Upon randomization, all patients were stable with a minimum
dialysis spKt/Vurea of 1.2 per treatment. Treatment times were
fixed at baseline and could only be increased during follow-up
when the spKt/V dropped below 1.2. Online HDF was performed
in post-dilution mode with a target dose for convection flow of
100 mL/min and high-flux synthetic dialyzers were used (UF
coefficient 55–85 ml/mmHg/h: FX80, FX100 and Optiflux
F200NR [Fresenius Medical Care, Bad Homburg, Germany]
and Polyflux170H and Polyflux210H [Gambro Corporation AB,
Lund, Sweden]). Conventional HD was performed with low-flux
synthetic dialyzers (UF coefficient 10–18 ml/mmHg/h: F6HPS,
F8HPS and Optiflux18NR [Fresenius] and Polyflux14L and
Polyflux17L [Gambro]). Routine patient care was performed
according to the opinion of the attending nephrologist and based
Table 1. Studies on the effect of HDF versus HD on ESA resistance.
Design N
Conventional treatment;
ultrapure dialysis fluid?a
Mean convection
volume (L/session) Outcome
Bonforte 2002 [37] Observational 32 Low-flux HD; no 19.5; post-dilution Q ESA resistance
Lin 2002 [23] Cross-over 92 High-flux HD; yes 21; post-dilution Q ESA resistance
Vaslaki 2006 [36] Randomized cross-over 129 Low-flux HD; no 20.2; post-dilution Q ESA resistance
Schiffl 2007 [35] Randomized cross-over 76 Low-flux HD; no 20.3; post-dilution Q ESA resistance
Turkish online HDF study
2013 [17]
RCT 782 High-flux HD; no 21.0; post-dilution Q ESA resistance
Vilar 2009 [15] Observational 858 (232 HDF) High-flux HD; yes Not available No difference
Oates 2011 [38] Observational 34 HDF, 44 HD High-flux HD; yes .16; post-dilution No difference
Ward 2000 [39] RCT 44 High-flux HD; yes 18.0; post-dilution No difference
Wizemann 2000 [40] RCT 44 Low-flux HD; yes 60; mid-dilution No difference
Locatelli 2012 [41] RCT 146 Low-flux HD; yes HF: 60.4, HDF: 39.9; pre-
dilution
No difference
ESHOL 2013 [18] RCT 906 High-flux HD; yes 23.4; post-dilution No difference
CONTRAST 2013 RCT 714 Low-flux HD; yes 20.3; post-dilution No difference
aUltrapure dialysis fluid is defined as ,0.1 colony forming units per ml and ,0.03 endotoxin units per ml [28].
doi:10.1371/journal.pone.0094434.t001
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on the Quality of Care Guidelines of the Dutch Federation of
Nephrology. The Dutch Guideline on Anemia Management is
derived from the European Best Practice Guidelines [25] and the
KDOQI guidelines [26,27].
ESA and iron supplements were administered via the venous
blood line at the end of a dialysis session. Both HDF and HD
patients were treated with ultrapure dialysis fluids, containing less
than 0.1 colony forming units per mL and less than 0.03 endotoxin
units per mL [28,29]. The quality of the dialysis solutions was
regularly monitored as part of the Quality of Care Guideline on
water quality of the Dutch Federation of Nephrology [29].
Data collection
At baseline, data on demography, cause of renal failure, history
of cardiovascular disease, diabetes mellitus, type of vascular access,
dialysis vintage and treatment parameters were collected. Subse-
quent study visits were performed at three month intervals. During
these visits, information on ESA and iron doses at the time of the
visit date was collected.
ESA was prescribed as epoetin a or b (IU) or darbepoetin a (mg).
To compare the different types of ESA, weekly prescribed dosages
were converted to daily defined doses (DDD), using conversion
factors as provided by the World Health Organization (WHO)
Drug Classification (http://www.whocc.no/atcddd). DDD repre-
sents the assumed average maintenance dose per day for a drug
used for its main indication in adults. For darbepoetin a (ATC
code B03XA02) DDD is 4.5 mg and for epoetin a and b (ATC
code B03XA01) DDD is 1000 IU.
ESA resistance was expressed as an ESA index: the weekly
weight adjusted ESA dose (DDD) divided by the haematocrit (Hct)
[30]. Iron supplements were prescribed as iron sucrose or iron
dextran (in mg/week), both with an equal amount of elemental
iron per mg.
At each study visit, with a window of two weeks around the
exact visit date, blood samples were drawn prior to dialysis for
routine laboratory assessments. All laboratory samples were
analysed in the local hospitals by standard laboratory techniques.
Ferritin levels (mg/L) and the transferrin saturation ratio (TSAT)
were used as indices of iron stores. TSAT values were either
reported directly or calculated as serum iron divided by the serum
total-iron-binding capacity (TIBC), which was considered to
represent serum transferrin level [31].
Serum albumin was measured with either the bromcresol green
or bromcresol purple method and bromcresol purple concentra-
tions were converted to bromcresol green [32]. The second
generation Daugirdas formula was used to calculate spKt/Vurea
[33]. In patients treated with HDF, the average achieved
convection volume per session was calculated as the sum of the
intradialytic weight loss and the infusion volume (substitution
volume). The HDF treatment was quantified by the convection
volume and pre-dialysis levels of b2-microglobulin (b2M; mg/L)
over time [34].
Statistical analysis
All analyses were conducted according to an intention-to-treat
principle. Patient data were censored at the date of death or date
of the last study visit if the patient stopped with the study. All
variables were reported as proportions or means 6 standard
deviation (SD) or 95% confidence interval (CI), or medians with
25th–75th percentiles when appropriate.
Laboratory parameters, ESA dose and -index and iron
supplementation over time were evaluated with linear mixed-
effects models, as repeated measurements over time were assumed
to be related within participants. All available measurements until
12 months of follow-up were entered into the models. For each
individual, a mean level of the laboratory parameters during the
follow-up was estimated. Subsequently, the difference in the mean
levels between the treatment groups was calculated, adjusted for
the baseline levels.
To evaluate a possible dose-response relation in HDF patients,
the effect of treatment on change in ESA index was explored in
different tertiles of convection volume during 12 months of follow-
up. Low-flux HD was regarded as the reference category. The
choice for tertiles was based on the reasonable sample size in each
of the tertiles.
To evaluate whether the treatment effect on mean ESA index
was modified by the stratum of ESA resistance at baseline, the
possibility of effect modification was explored by adding an
interaction term (ESA index6treatment modality) to the linear
mixed-effects model.
Since a total of nine parameters were evaluated, we applied a
Bonferroni adjustment for multiple testing and considered a two
sided p-value,0.006 as statistically significant. Statistical analyses
were performed with SPSS software (version 20, 2011, IBM SPSS
Statistics) and R (version 2.9.2; 2009 The R Foundation for
Statistical Computing).
Results
Patient characteristics and clinical parameters at baseline
In total, 714 patients were included in the study, 358 were
allocated to HDF and 356 to HD. The two groups were well
balanced with respect to baseline characteristics (table 2). During
12 months of follow-up, 62 patients in the HDF group and 74 in
the HD group were censored because they died, received a kidney
transplant, switched to peritoneal dialysis, moved to another
center or for other reasons (figure 1).
Clinical parameters during follow-up
For patients treated with HDF, the mean (6 SD) achieved
convection volume during one year of follow-up was 20.364.8
liters per session. During the study, the mean dialysis single pool
Kt/V urea (spKt/Vurea) was higher in in the HDF group (mean
[95% CI] difference HDF vs. HD 0.17 [0.07 to 0.27; P,0.001]).
The mean b2M level during follow-up was significantly lower in
the HDF group (mean difference HDF vs. HD 27.8 mg/L
[210.5 to 24.9; P,0.001]). Furthermore, albumin levels were
equal in both groups during follow-up (mean difference HDF vs.
HD 20.02 g/dL [20.06 to 0.02; P= 0.35]).
Hemoglobin and ESA resistance. Anemia parameters
during follow-up are listed in table 3. Hemoglobin levels were
not different between both groups. Furthermore, there was no
difference in mean ESA index and ESA dose between the
treatment groups during follow-up (table 3, figure 2).
To explore a possible effect of the HDF dose, expressed as the
average achieved convection volume during follow-up, the change
in ESA index was analyzed separately within tertiles of convection
volume. Within each tertile of achieved convection volume, the
ESA index did not change and was not different compared to HD
(data not shown).
Iron parameters and iron therapy. Ferritin levels at
baseline were not different between both groups (HDF: (median
[interquartile range]: 314 ng/mL [191–567]; HD 367 ng/mL
[196–606]; P= 0.16). During one year of follow-up, mean ferritin
and TSAT levels tended to be marginally lower in the HDF group
as compared to HD (mean difference HDF vs. HD 249 ng/mL
[2103 to 4; P= 0.06] and 22.5% [24.7 to 20.3; P = 0.02]
respectively; table 3).
ESA Resistance: HDF versus HD
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The mean dose of iron supplementation during follow-up
tended to be slightly higher in the HDF group as compared to HD
(mean difference HDF vs. HD 7.1 mg/week [20.4 to 14.5;
P = 0.06]).
Sub-analysis: ESA resistance over time in different
groups of ESA index at baseline. The effect of HDF versus
HD on mean ESA index over time was not modified by the ESA
index at baseline (P-value for the interaction term=0.15).
Discussion
The present secondary analysis of a RCT showed that ESA
resistance over a 12 months’ period, as measured by the mean
ESA index over time, was not different between patients treated
with online HDF or HD. In the HDF group, iron parameters
(ferritin and TSAT) tended to be slightly lower during follow up
whereas there was a trend towards more intravenous iron
supplementation in this group.
As mentioned before, studies on the effect of HDF on ESA
resistance have been conflicting (table 1). Our overall results are in
contrast with results of two cross-over studies [35,36], two
observational studies [23,37] and one RCT [17] in which ESA
dose and/or ESA resistance decreased and/or hemoglobin levels
increased in patients treated with online HDF. On the contrary, in
two non-randomized studies [15,38] and two small [39,40] and
two large RCTs [18,41], no difference between treatment with
HDF or HD in either ESA dose or hemoglobin levels was shown
either. Remarkably, in virtually all studies in which a beneficial
effect of HDF on ESA resistance was shown, the dialysis fluid
applied in the conventional HD group was not ultrapure
according to the generally accepted definition (,0.1 colony
forming units per ml and ,0.03 endotoxin units per ml) [28]. In
contrast, in the studies that did not show a difference, ultrapure
dialysis fluid was used for both treatment with HD and HDF
(table 1). A recent meta-analysis has shown that the use of
ultrapure dialysis fluid resulted in increased hemoglobin levels and
diminished ESA requirements [9]. Furthermore, in a recently
published RCT in 704 patients, it was shown that ultrapure
dialysis fluid as compared to standard dialysis fluid resulted in
reduced ESA doses and ESA resistance despite equal hemoglobin
and ferritin levels [42]. Therefore, we hypothesized that the use of
ultrapure dialysis fluid may be of predominant importance with
respect to erythropoiesis and ESA responsiveness as compared to
increasing MMW clearance by adding convection [43,44,45].
Another possible explanation for the absent effect of HDF on
ESA resistance may be that with HDF, besides removal of ESA or
erythropoiesis inhibiting toxins, erythropoiesis stimulating sub-
stances are removed as well. However, we have no data to support
this hypothesis.
We postulated that the amount of convection volume, being a
key quantifier for HDF treatment according to a recent position
statement by the HDF working group (EUDIAL) of the European
Renal Association-European Dialysis and Transplant Association
[34], might affect ESA responsiveness. In an on-treatment analysis
Figure 1. CONSORT flow chart of patient inclusion.
doi:10.1371/journal.pone.0094434.g001
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Table 2. Baseline characteristicsa.
Online HDF (n=358) Low-flux HD (n=356)
Gender (no. [%] male) 214 (60) 231 (65)
Age (years) 64.1614.0 64.0613.4
Caucasian race (no. [%]) 304 (85) 296 (83)
Dialysis vintage (years) 1.8 (1.0–3.7) 2.1 (1.0–4.0)
Cause of ESRD (no. [])
- vascular 104 (29) 96 (27)
- diabetes mellitus 76 (21) 60 (17)
- glomerulonephritis 36 (10) 53 (15)
- interstitial nephropathy 35 (10) 31 (9)
- multisystem disease 15 (4) 11 (3)
- cystic disease 27 (7) 26 (7)
- other/unknown 65 (18) 79 (22)
Diabetes mellitus (no. [%]) 92 (26) 78 (22)
History of cardiovascular disease (no. [%])b 141 (42) 162 (46)
Body weight after dialysis (kg)c 71.6615.0 73.3613.6
BMI after dialysis (kg/m2) 25.265.0 25.664.6
Residual kidney function (no. [%])d 186 (52) 190 (53)
eGFR (ml/min/1.73 m2)e 0.32 (0–3.30) 0.30 (0–3.35)
Treatment frequency (no. [%])
- 26/week 26 (7) 18 (5)
- 36/week 332 (93) 338 (95)
Duration of a dialysis session (min) 226626 227622
Bloodflow (mL/min) 302639 299641
Dialysis access (no. [%])
- AV fistula 279 (78) 288 (81)
- graft 57 (16) 43 (12)
- central catheter 22 (5) 25 (7)
spKt/Vurea 1.4260.25 1.3860.20
Hemoglobin (g/dL) 11.961.3 11.861.1
Hematocrit 0.3660.04 0.3660.04
Ferritin (ng/mL)
- Median (interquartile range) 314 (191–567) 367 (196–606)
- Mean 6 SD 4236347 4426322
TSAT (%) 23.9611.1 24.4611.7
Albumin (g/dL) 3.6660.45 3.7060.46
Parathyroid hormone (pg/ml) 193.7 (94.0–322.9) 194.7 (104.5–355.2)
b2-microglobulin (mg/L) 30.7614.2 32.3613.6
ESA treatment (no. [%]) 311 (87) 320 (90)
Type of ESA (no [%])
- Darbepoetin a 226 (73) 231 (72)
- Epoetin b 64 (20) 71 (22)
- Epoetin a 21 (7) 18 (6)
ESA dose (DDD/week)
- Median (interquartile range) 8.0 (4.0–13.3) 7.6 (4.4–13.3)
- Mean 6 SD 9.769.0 9.868.1
ESA index (DDD/kg/Hct/week)
- Median (interquartile range) 0.31 (0.14–0.59) 0.30 (0.15–0.55)
- Mean 6 SD 0.4060.39 0.4060.37
Iron replacement (no. [%]) 236 (66) 231 (65)
ESA Resistance: HDF versus HD
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of both CONTRAST and the Turkish HDF study, a survival
benefit for HDF patients treated with the highest convection
volumes was observed [16,17]. In the ESHOL study, in which an
overall survival benefit for HDF was shown, convection volumes
were higher (23.4 L per session versus 19.8 L and 21.04 in
CONTRAST and the Turkish study, respectively) [18]. Consid-
ering convection volume and ESA resistance, it was shown in a
study in 37 chronic dialysis patients that a switch from treatment
with low-volume HDF (mean substitution volume 4.0 L/session)
to high-volume online HDF (mean substitution volume 22.5 L/
session) resulted in increased hemoglobin levels and decreased
ESA doses. In our study, however, we could not identify such a
dose-response effect with respect to ESA resistance.
Concerning iron therapy, it was previously reported that ferritin
and TSAT levels decreased in HDF patients despite a lower ESA
dose and a higher haematocrit, suggesting improved iron
utilization [23]. As mentioned, in our study, HDF patients tended
to receive slightly more intravenous iron than HD patients which
might be partially explained by relatively low ferritin levels in HDF
patients at baseline, suggesting that overall, patients randomized to
HDF were more iron deplete at the time of enrolment. This
relative iron deplete state seemed to remain present during the
study. Other potential explanations for the relative iron deplete
state in the HDF group despite slightly more iron supplementation
might be loss of ascorbic acid (vitamin C) [46], since this vitamin
enhances iron availability [47,48], and blood loss due to clotting in
the extracorporeal circuit as a result of increased pro-coagulatory
activity during HDF [49].
We restricted the analysis to one year of follow-up since
previous studies already showed an effect of HDF on ESA
resistance after 3 to 6 months [36,37]. A limitation of our study is
the conversion of ESA dose to DDD, which may be an
oversimplification, as a non-linear conversion factor, dependent
upon the actual ESA dose, has been described [50]. An additional
drawback is the lack of a specific treatment protocol for ESA and
iron administration. However, as the treatment allocation was
Figure 2. Change in ESA index for HDF and HD. Crude means (SE) at time of visit are depicted. P-value for mean difference in ESA index over
time (HDF vs. HD) = 0.29 (based on a linear mixed-effects model including all 3122 measurements during 12 months of follow-up).
doi:10.1371/journal.pone.0094434.g002
Table 2. Cont.
Online HDF (n=358) Low-flux HD (n=356)
Type of iron replacement (no. [%])
- Ironsucrose 215 (91) 213 (92)
- Irondextran 21 (9) 18 (8)
Iron dose (mg/week)
- Median (interquartile range) 23.3 (0–100) 23.3 (0–100)
- Mean 6 SD 48651 43642
aValues represent mean 6 SD, median (interquartile range) or proportion (%).
bHistory of cardiovascular disease was defined as history of angina pectoris or myocardial infarction and/or a previous coronary bypass graft and/or percutaneous
coronary intervention and/or stroke or transient ischemic attack and/or peripheral vascular disease.
cWeight after dialysis (dry weight) defined as the mean of three consecutive values.
dDefined as .100 mL per day.
eeGFR (estimated glomerular filtration rate) calculated as mean of creatinine and urea clearance in 24 h urine collection adjusted for body surface area [48].
Conversion factors for units: hemoglobin in g/dL to mmol/L,60.62; albumin in g/dL to g/L,610; parathyroid hormone pg/ml to pmol/l60.11; no conversion necessary
for ferritin in ng/mL and mg/L.
doi:10.1371/journal.pone.0094434.t002
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stratified per participating center, the effect on the study outcome
will probably be limited. Moreover, our study reflects usual care in
the Netherlands. In our study, HDF was compared with low-flux
HD although at present, the majority of patients is treated with
high-flux dialyzers as recommended in current guidelines [51].
Since we observed no difference between HDF and low-flux HD
concerning ESA resistance, it is highly unlikely that there would be
a difference when HDF and high-flux HD (which can be
considered as a form of ‘‘low-volume HDF’’) were compared.
Furthermore, in the ESHOL study, no effect of HDF versus high-
flux HD on ESA resistance was observed either [18]. A final
limitation is the handling of missing data due to drop out. These
data might be missing in a non-randomly fashion.
The strength of our study is the large sample size and its
randomized design with an accurate prospective data collection.
Furthermore, all available measurements during follow-up (at 3, 6,
9 and 12 months) were included in the analysis.
In conclusion, this multicenter randomized controlled study
showed that ESA resistance was not different between patients
treated with online HDF or ultrapure low-flux HD during 12
months of follow-up. These data indicate that when considering
ESA resistance, online HDF has no benefit over low-flux ultrapure
HD. Whether other factors are involved, such as the quality of the
dialysis fluid, remains to be determined.
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